AML1/ETO cooperates with HIF1α to promote leukemogenesis through DNMT3a transactivation

Leukemia

Volumn 29, Issue 8, 2015, Pages 1730-1740

  Gao, X N ^a,b   Yan, F ^b   Lin, J ^a   Gao, L ^a   Lu, X L ^a   Wei, S C ^b   Shen, N ^b   Pang, J X ^b   Ning, Q Y ^a   Komeno, Y ^c   Deng, A L ^a   Xu, Y H ^a   Shi, J L ^a   Li, Y H ^a   Zhang, D E ^c   Nervi, C ^d   Liu, S J ^b   Yu, L ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; DNA METHYLTRANSFERASE 1; DNA METHYLTRANSFERASE 3A; DNA METHYLTRANSFERASE 3B; HYBRID PROTEIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P15; TRANSCRIPTION FACTOR RUNX1; AML1-ETO FUSION PROTEIN, HUMAN; DNA (CYTOSINE 5) METHYLTRANSFERASE; HIF1A PROTEIN, HUMAN; ONCOPROTEIN;

ACUTE MYELOBLASTIC LEUKEMIA; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER SURVIVAL; CELL FATE; CELL PROLIFERATION; CLINICAL FEATURE; CONTROLLED STUDY; DNA METHYLATION; EVENT FREE SURVIVAL; GENE EXPRESSION; GENE MUTATION; GENE OVEREXPRESSION; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL; LEUKEMOGENESIS; MAJOR CLINICAL STUDY; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY MECHANISM; TRANSACTIVATION; TRANSCRIPTION INITIATION; TRANSCRIPTION INITIATION SITE; WESTERN BLOTTING; ANIMAL; APOPTOSIS; CELL TRANSFORMATION; CHROMATIN IMMUNOPRECIPITATION; DRUG SCREENING; ENZYME IMMUNOASSAY; FLOW CYTOMETRY; GENETICS; METABOLISM; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CHROMATIN IMMUNOPRECIPITATION; CORE BINDING FACTOR ALPHA 2 SUBUNIT; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA METHYLATION; FLOW CYTOMETRY; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOENZYME TECHNIQUES; LEUKEMIA, MYELOID, ACUTE; MICE; ONCOGENE PROTEINS, FUSION; PROMOTER REGIONS, GENETIC; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANSCRIPTIONAL ACTIVATION; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84938989034     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2015.56     Document Type: Article

References (52)

1. Peterson LF, Zhang DE. The 8;21 translocation in leukemogenesis. Oncogene 2004; 23: 4255-4262.
2. Yuan Y, Zhou L, Miyamoto T, Iwasaki H, Harakawa N, Hetherington CJ et al. AML1-ETO expression is directly involved in the development of acute myeloid leukemia in the presence of additional mutations. Proc Natl Acad Sci USA 2001; 98: 10398-10403.
3. Wang YY, Zhou GB, Yin T, Chen B, Shi JY, Liang WX et al. AML1-ETO and C-KIT mutation/overexpression in t(8;21) leukemia: implication in stepwise leukemo-genesis and response to Gleevec. Proc Natl Acad Sci USA 2005; 102: 1104-1109.
4. Schessl C, Rawat VP, Cusan M, Deshpande A, Kohl TM, Rosten PM et al. The AML1-ETO fusion gene and the FLT3 length mutation collaborate in inducing acute leukemia in mice. J Clin Invest 2005; 115: 2159-2168.
5. Schneider F, Bohlander SK, Schneider S, Papadaki C, Kakadyia P, Dufour A et al. AML1-ETO meets JAK2: clinical evidence for the two hit model of leukemogenesis from a myeloproliferative syndrome progressing to acute myeloid leukemia. Leukemia 2007; 21: 2199-2201.
6. Peterson LF, Boyapati A, Ahn EY, Biggs JR, Okumura AJ, Lo MC et al. Acute myeloid leukemia with the 8q22;21q22 translocation: secondary mutational events and alternative t(8;21) transcripts. Blood 2007; 110: 799-805.
7. Kuchenbauer F, Schnittger S, Look T, Gilliland G, Tenen D, Haferlach T et al. Identification of additional cytogenetic and molecular genetic abnormalities in acute myeloid leukaemia with t(8;21)/AML1-ETO. Br J Haematol 2006; 134: 616-619.
8. Dohner K, Du J, Corbacioglu A, Scholl C, Schlenk RF, Dohner H. JAK2V617F mutations as cooperative genetic lesions in t(8;21)-positive acute myeloid leukemia. Haematologica 2006; 91: 1569-1570.
9. Paschka P, Marcucci G, Ruppert AS, Mrozek K, Chen H, Kittles RA et al. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. J Clin Oncol 2006; 24: 3904-3911.
10. Keith B, Simon MC. Hypoxia-inducible factors, stem cells, and cancer. Cell 2007; 129: 465-472.
11. Stroka DM, Burkhardt T, Desbaillets I, Wenger RH, Neil DA, Bauer C et al. HIF-1 is expressed in normoxic tissue and displays an organ-specific regulation under systemic hypoxia. FASEB J 2001; 15: 2445-2453.
12. Kuschel A, Simon P, Tug S. Functional regulation of HIF-1alpha under normoxia-is there more than post-translational regulation? J Cell Physiol 2012; 227: 514-524.
13. Gerber SA, Pober JS. IFN-alpha induces transcription of hypoxia-inducible factor-1alpha to inhibit proliferation of human endothelial cells. J Immunol 2008; 181: 1052-1062.
14. Wang Y, Liu Y, Malek SN, Zheng P. Targeting HIF1alpha eliminates cancer stem cells in hematological malignancies. Cell Stem Cell 2011; 8: 399-411.
15. Matsunaga T, Imataki O, Torii E, Kameda T, Shide K, Shimoda H et al. Elevated HIF-1alpha expression of acute myelogenous leukemia stem cells in the endosteal hypoxic zone may be a cause of minimal residual disease in bone marrow after chemotherapy. Leuk Res 2012; 36: e122-e124.
16. Figueroa ME, Lugthart S, Li Y, Erpelinck-Verschueren C, Deng X, Christos PJ et al. DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer cell 2010; 17: 13-27.
17. Linggi B, Muller-Tidow C, van de Locht L, Hu M, Nip J, Serve H et al. The t(8;21) fusion protein, AML1 ETO, specifically represses the transcription of the p14(ARF) tumor suppressor in acute myeloid leukemia. Nat Med 2002; 8: 743-750.
18. Kitabayashi I, Ida K, Morohoshi F, Yokoyama A, Mitsuhashi N, Shimizu K et al. The AML1-MTG8 leukemic fusion protein forms a complex with a novel member of the MTG8(ETO/CDR) family, MTGR1. Mol Cell Biol 1998; 18: 846-858.
19. Wang J, Hoshino T, Redner RL, Kajigaya S, Liu JM. ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex. Proc Natl Acad Sci USA 1998; 95: 10860-10865.
20. Liu S, Shen T, Huynh L, Klisovic MI, Rush LJ, Ford JL et al. Interplay of RUNX1/MTG8 and DNA methyltransferase 1 in acute myeloid leukemia. Cancer Res 2005; 65: 1277-1284.
21. Liu Y, Cheney MD, Gaudet JJ, Chruszcz M, Lukasik SM, Sugiyama D et al. The tetramer structure of the Nervy homology two domain, NHR2, is critical for AML1/ETO's activity. Cancer cell 2006; 9: 249-260.
22. Fazi F, Racanicchi S, Zardo G, Starnes LM, Mancini M, Travaglini L et al. Epigenetic silencing of the myelopoiesis regulator microRNA-223 by the AML1/ETO onco-protein. Cancer cell 2007; 12: 457-466.
23. Liu S, Wu LC, Pang J, Santhanam R, Schwind S, Wu YZ et al. Sp1/NFkappaB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia. Cancer cell 2010; 17: 333-347.
24. Shen N, Yan F, Pang J, Wu LC, Al-Kali A, Litzow MR et al. A nucleolin-DNMT1 regulatory axis in acute myeloid leukemogenesis. Oncotarget 2014; 5: 5494-5509.
25. deJonge HJ, Valk PJ, Veeger NJ, ter Elst A, den Boer M L, Cloos J et al. High VEGFC expression is associated with unique gene expression profiles and predicts adverse prognosis in pediatric and adult acute myeloid leukemia. Blood 2010; 116: 1747-1754.
26. Litz J, Krystal GW. Imatinib inhibits c-Kit-induced hypoxia-inducible factor-1alpha activity and vascular endothelial growth factor expression in small cell lung cancer cells. Mol Cancer Ther 2006; 5: 1415-1422.
27. Gardini A, Cesaroni M, Luzi L, Okumura AJ, Biggs JR, Minardi SP et al. AML1/ETO oncoprotein is directed to AML1 binding regions and co-localizes with AML1 and HEB on its targets. PLoS Genet 2008; 4: e1000275.
28. Ptasinska A, Assi SA, Mannari D, James SR, Williamson D, Dunne J et al. Depletion of RUNX1/ETO in t(8;21) AML cells leads to genome-wide changes in chromatin structure and transcription factor binding. Leukemia 2012; 26: 1829-1841.
29. Ortiz-Barahona A, Villar D, Pescador N, Amigo J, del Peso L. Genome-wide identification of hypoxia-inducible factor binding sites and target genes by a probabilistic model integrating transcription-profiling data and in silico binding site prediction. Nucleic Acids Res 2010; 38: 2332-2345.
30. Xia X, Lemieux ME, Li W, Carroll JS, Brown M, Liu XS et al. Integrative analysis of HIF binding and transactivation reveals its role in maintaining histone methyla-tion homeostasis. Proc Natl Acad Sci USA 2009; 106: 4260-4265.
31. Mole DR, Blancher C, Copley RR, Pollard PJ, Gleadle JM, Ragoussis J et al. Genome-wide association of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha DNA binding with expression profiling of hypoxia-inducible transcripts. J Biol Chem 2009; 284: 16767-16775.
32. Yan M, Kanbe E, Peterson LF, Boyapati A, Miao Y, Wang Y et al. A previously unidentified alternatively spliced isoform of t(8;21) transcript promotes leuke-mogenesis. Nat Med 2006; 12: 945-949.
33. Kong D, Park EJ, Stephen AG, Calvani M, Cardellina JH, Monks A et al. Echino-mycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity. Cancer Res 2005; 65: 9047-9055.
34. Herman JG, Jen J, Merlo A, Baylin SB. Hypermethylation-associated inactivation indicates a tumor suppressor role for p15INK4B. Cancer Res 1996; 56: 722-727.
35. Higuchi M, O'Brien D, Kumaravelu P, Lenny N, Yeoh EJ, Downing JR. Expression of a conditional AML1-ETO oncogene bypasses embryonic lethality and establishes a murine model of human t(8; 21) acute myeloid leukemia. Cancer cell 2002; 1: 63-74.
36. Vaupel P. The role of hypoxia-induced factors in tumor progression. Oncologist 2004; 9(Suppl 5): 10-17.
37. Unruh A, Ressel A, Mohamed HG, Johnson RS, Nadrowitz R, Richter E et al. The hypoxia-inducible factor-1 alpha is a negative factor for tumor therapy. Oncogene 2003; 22: 3213-3220.
38. Baba Y, Nosho K, Shima K, Irahara N, Chan AT, Meyerhardt JA et al. HIF1A over-expression is associated with poor prognosis in a cohort of 731 colorectal cancers. Am J Pathol 2010; 176: 2292-2301.
39. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1, 612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998; 92: 2322-2333.
40. Cairoli R, Beghini A, Grillo G, Nadali G, Elice F, Ripamonti CB et al. Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study. Blood 2006; 107: 3463-3468.
41. Yoo SJ, Chi HS, Jang S, Seo EJ, Seo JJ, Lee JH et al. Quantification of AML1-ETO fusion transcript as a prognostic indicator in acute myeloid leukemia. Haemato-logica 2005; 90: 1493-1501.
42. Li Y, Gao L, Luo X, Wang L, Gao X, Wang W et al. Epigenetic silencing of microRNA-193a contributes to leukemogenesis in t(8; 21) acute myeloid leukemia by activating the PTEN/PI3K signal pathway. Blood 2013; 121: 499-509.
43. Maiques-Diaz A, Chou FS, Wunderlich M, Gomez-Lopez G, Jacinto FV, Rodriguez-Perales S et al. Chromatin modifications induced by the AML1-ETO fusion protein reversibly silence its genomic targets through AML1 and Sp1 binding motifs. Leukemia 2012; 26: 1329-1337.
44. Wang L, Gural A, Sun XJ, Zhao X, Perna F, Huang G et al. The leukemogenicity of AML1-ETO is dependent on site-specific lysine acetylation. Science 2011; 333: 765-769.
45. Shia WJ, Okumura AJ, Yan M, Sarkeshik A, Lo MC, Matsuura S et al. PRMT1 interacts with AML1-ETO to promote its transcriptional activation and progenitor cell proliferative potential. Blood 2012; 119: 4953-4962.
46. Peng ZG, Zhou MY, Huang Y, Qiu JH, Wang LS, Liao SH et al. Physical and functional interaction of Runt-related protein 1 with hypoxia-inducible factor-1alpha. Oncogene 2008; 27: 839-847.
47. Freedman SJ, Sun ZY, Poy F, Kung AL, Livingston DM, Wagner G et al. Structural basis for recruitment of CBP/p300 by hypoxia-inducible factor-1 alpha. Proc Natl Acad Sci USA 2002; 99: 5367-5372.
48. Fahling M, Persson AB, Klinger B, Benko E, Steege A, Kasim M et al. Multilevel regulation of HIF-1 signaling by TTP. Mol Biol Cell 2012; 23: 4129-4141.
49. Lee JS, Kim Y, Bhin J, Shin HJ, Nam HJ, Lee SH et al. Hypoxia-induced methylation of a pontin chromatin remodeling factor. Proc Natl Acad Sci USA 2011; 108: 13510-13515.
50. Robinson CM, Neary R, Levendale A, Watson CJ, Baugh JA. Hypoxia-induced DNA hypermethylation in human pulmonary fibroblasts is associated with Thy-1 promoter methylation and the development of a pro-fibrotic phenotype. Respir Res 2012; 13: 74.
51. Shahrzad S, Bertrand K, Minhas K, Coomber BL. Induction of DNA hypomethyla-tion by tumor hypoxia. Epigenetics 2007; 2: 119-125.
52. Liu Q, Liu L, Zhao Y, Zhang J, Wang D, Chen J et al. Hypoxia induces genomic DNA demethylation through the activation of HIF-1alpha and transcriptional upregu-lation of MAT2A in hepatoma cells. Mol Cancer Ther 2011; 10: 1113-1123.